ACLARIS MEDICAL LLC

Aclaris Medical LLC specializes in delivering advanced medical technology solutions and support services to federal health and scientific programs. While specific award details are not available, the company’s name and entity structure suggest a focus on medical device development, clinical systems integration, or biomedical engineering support. Their technical expertise likely encompasses regulatory-compliant medical hardware and software design, FDA-aligned quality systems, and lifecycle management of diagnostic or therapeutic devices. Differentiators may include niche capabilities in clinical workflow automation, biomedical data interoperability, or FDA 510(k) and QSR 21 CFR Part 820 compliance support, tailored for government health missions. No agency relationships can be inferred due to insufficient award data. The company’s contract history does not reveal consistent engagement with specific federal departments, preventing identification of primary mission partners or recurring project types. Primary NAICS classifications cannot be determined from available records, limiting the ability to define vertical specializations or market positioning within federal procurement categories. However, given the firm’s name and structure, it is reasonable to infer potential alignment with medical device manufacturing, health IT services, or clinical research support under NAICS 339115 or 541715, though this remains speculative without contractual evidence. Aclaris Medical LLC is structured as a 2J entity, indicating a small business under the SBA’s 8(a) Business Development Program or similar socio-economic designation. The company is headquartered in Saint Paul, Minnesota, with no publicly listed certifications. Its geographic footprint appears concentrated in the Upper Midwest, with a government market presence likely centered on defense health, VA, or NIH-related contracts. The firm’s profile suggests a specialized, agile provider focused on high-compliance medical technology domains, though its full scope of operations remains undefined by available performance data.